Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Recursion Pharmaceuticals Inc Cl A
(NQ:
RXRX
)
7.810
+0.460 (+6.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Recursion Pharmaceuticals Inc Cl A
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Cathie Wood Owns These 2 AI Stocks. Should You?
June 03, 2024
One looks like a solid option. The other one, not so much.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is Recursion Pharmaceuticals Stock a Millionaire-Maker?
June 02, 2024
Recursion Pharmaceuticals hopes to transform the healthcare industry with the help of AI.
Via
The Motley Fool
How Is The Market Feeling About Recursion Pharmaceuticals?
May 30, 2024
Via
Benzinga
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
May 29, 2024
Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in...
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion Pharm Stock Sees Relative Strength Rating Rise To 84
May 14, 2024
On Tuesday, Recursion Pharm stock had its Relative Strength (RS) Rating upgraded to 84, up from 78 a day earlier.
Via
Investor's Business Daily
Demystifying Recursion Pharmaceuticals: Insights From 4 Analyst Reviews
May 10, 2024
Via
Benzinga
(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest
May 02, 2024
Via
Benzinga
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk
May 29, 2024
You don't need to buy her picks, but it's worth understanding them.
Via
The Motley Fool
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
May 27, 2024
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our...
Via
Talk Markets
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
May 24, 2024
Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur
From
Recursion Pharmaceuticals
Via
GlobeNewswire
2 Stocks That Could 10x by 2035
May 24, 2024
These stocks are very promising, but it's important to consider the downside, too.
Via
The Motley Fool
Jim Cramer Offers His Take On Corning, Calls This Healthcare Stock A 'Terrific Spec'
May 23, 2024
Jim Cramer says Corning has "not been able to generate the kind of return that I've wanted"; calls Recursion a "terrific spec"
Via
Benzinga
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In
May 20, 2024
The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process...
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
What's the Difference Between Biotech Stocks and TechBio Stocks?
May 15, 2024
A few enterprising businesses are marketing themselves differently.
Via
The Motley Fool
Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday
May 14, 2024
Via
Benzinga
The Next Drug You Take May be Designed By A.I.
May 14, 2024
Three stocks could give investors a better way to tap into A.I.'s future potential inside drug development, an industry that is set to grow at 29.6% until 2030
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism
May 13, 2024
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) made waves Monday afternoon not only with the announcement of its groundbreaking BioHive-2 supercomputer but also with a notable surge in its stock...
Via
Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
May 13, 2024
Via
Talk Markets
Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 13, 2024
Via
Benzinga
GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
May 13, 2024
Via
Benzinga
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
May 13, 2024
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024.
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Cathie Wood Is Buying This Under-the-Radar AI Stock
May 12, 2024
This company has massive upside potential, but that's not the whole story.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
RXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 09, 2024
RXRX stock results show that Recursion Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Nvidia-Backed Recursion Pharmaceuticals Stock Is Up On Q1 Earnings: Everything You Need To Know
May 09, 2024
Recursion reported first-quarter revenue of $13.491 million, which beat analyst estimates of $12.65 million, according to Benzinga Pro. The company reported a quarterly loss of 39 cents per share,...
Via
Benzinga
Nvidia Favorite SoundHound AI Delivers Beat-And-Raise Report
May 09, 2024
SoundHound AI, which counts Nvidia as an investor, beat estimates for the first quarter and with its sales guidance. SOUN stock rose.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
May 09, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
May 05, 2024
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.
Via
Talk Markets
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
May 02, 2024
Company to host public L(earnings) Call on May 9 at 5:00 pm ET
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Recursion to Participate in Upcoming Investor Conferences
May 01, 2024
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
April 30, 2024
The grant designates Altitude Lab as a top acceleration program for biotechnology startups
From
Recursion Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.